Macroeconomic ChallengesASH may face incrementally higher pressure from tariff/macroeconomic challenges compared to other names under coverage, compounded by unfavorable pricing.
Sales And Volume DeclineThe segment disappointed with organic sales down 12%, including volume decline in pharma along with pricing pressures.
Uncertainty In Life SciencesASH continues to see uncertainty around its core Life Sciences segment and the timing of overall organic recovery also remains unclear.